The report highlights UCB's financial and extra-financial performance in 2023, focusing on value creation for patients, employees, communities, and the planet. The report details the company's commitment to driving sustainable business by prioritizing innovation, equitable access to medicines, and responsible environmental practices. The report also includes highlights on the company's materiality assessment, corporate governance, and risk management strategies.
Issuing Company UCB S.A.
Report Type Integrated Report
Report Language EN
Report Filesize 9.98 MB
No. of Pages 322 pages
Reporting periodJanuary 1, 2023-December 31, 2023
Report EditionUnknown
Assurance Provider PwC Bedrijfsrevisoren
Reporting Standards ESRS; SASB; TCFD
Materiality Assessmenttrue
